Works matching IS 00278874 AND DT 2023 AND VI 115 AND IP 11
Results: 28
Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
- Published in:
- 2023
- By:
- Publication type:
- Product Review
Correction to: Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study.
- Published in:
- 2023
- Publication type:
- Correction Notice
Correction to: Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1437, doi. 10.1093/jnci/djad197
- Publication type:
- Article
Response to Lehrer and Rheinstein.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1429, doi. 10.1093/jnci/djad168
- By:
- Publication type:
- Article
Correction to: Smoking as a prognostic factor for survival in patients with disseminated germ cell cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1431, doi. 10.1093/jnci/djad161
- Publication type:
- Article
Correction to: Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.
- Published in:
- 2023
- Publication type:
- Correction Notice
The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1262, doi. 10.1093/jnci/djad151
- By:
- Publication type:
- Article
Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1383, doi. 10.1093/jnci/djad142
- By:
- Publication type:
- Article
EZH2 inhibition: it's all about the context.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1246, doi. 10.1093/jnci/djad141
- By:
- Publication type:
- Article
Protecting vulnerable patient populations from climate hazards: the role of the nation's cancer centers.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1252, doi. 10.1093/jnci/djad139
- By:
- Publication type:
- Article
A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1420, doi. 10.1093/jnci/djad137
- By:
- Publication type:
- Article
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1374, doi. 10.1093/jnci/djad135
- By:
- Publication type:
- Article
The decision aid is the easy part: workflow challenges of shared decision making in cancer care.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1271, doi. 10.1093/jnci/djad133
- By:
- Publication type:
- Article
Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1243, doi. 10.1093/jnci/djad129
- By:
- Publication type:
- Article
The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1392, doi. 10.1093/jnci/djad126
- By:
- Publication type:
- Article
Putting patients first to redefine prostate cancer classifications.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1249, doi. 10.1093/jnci/djad124
- By:
- Publication type:
- Article
Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1278, doi. 10.1093/jnci/djad118
- By:
- Publication type:
- Article
Changes in methylation-based aging in women who do and do not develop breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1329, doi. 10.1093/jnci/djad117
- By:
- Publication type:
- Article
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1318, doi. 10.1093/jnci/djad116
- By:
- Publication type:
- Article
Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1337, doi. 10.1093/jnci/djad115
- By:
- Publication type:
- Article
The long economic shadow of a cancer diagnosis during adolescence or young adulthood.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1237, doi. 10.1093/jnci/djad114
- By:
- Publication type:
- Article
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1240, doi. 10.1093/jnci/djad111
- By:
- Publication type:
- Article
The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1364, doi. 10.1093/jnci/djad108
- By:
- Publication type:
- Article
Financial outcomes of adolescent and young adult cancer survivors: a longitudinal population-based registry study.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1294, doi. 10.1093/jnci/djad107
- By:
- Publication type:
- Article
Prediction of breast cancer risk for sisters of women attending screening.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1310, doi. 10.1093/jnci/djad101
- By:
- Publication type:
- Article
Improving combination therapies: targeting A<sub>2B</sub>-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1404, doi. 10.1093/jnci/djad091
- By:
- Publication type:
- Article
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1355, doi. 10.1093/jnci/djad085
- By:
- Publication type:
- Article
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 11, p. 1302, doi. 10.1093/jnci/djad078
- By:
- Publication type:
- Article